HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis.

Abstract
Patients with a first episode of psychosis (FEP) display a broad range of metabolic risk factors related to the development of diverse medical comorbidities. Initial stages of these disorders are essential in understanding the increased vulnerability of developing cardiometabolic disturbances, associated with a reduced life expectancy. This study aimed to evaluate the metabolic profile of a cohort of patients with a FEP and its evolution during a two year follow-up, as well as the factors that influence the changes in their metabolic status. 16 participating centers from the PEPs Project recruited 335 subjects with a FEP and 253 matched healthy controls, aged 9-35years. We investigated a set of anthropometric measures, vital signs and laboratory data obtained from each participant over two years in a prospective, naturalistic study. From the beginning of the study the FEP group showed differences in the metabolic profile compared to the control group, together with a progressive worsening in the major part of the analyzed variables during the follow-up period, with higher rates of obesity and metabolic syndrome. Certain risk factors were related to determinate clinical variables such as male gender, the presence of affective symptoms or an early onset or to treatment variables such as the use of antipsychotic polypharmacy, antidepressants or mood stabilizers. Our results highlight the extremely high risk of patients at early phases of schizophrenia and other psychotic disorders of developing cardiovascular comorbidity and the fast worsening of the metabolic profile during the first two years.
AuthorsMiquel Bioque, M A Paz García-Portilla, Clemente García-Rizo, Bibiana Cabrera, Antonio Lobo, Ana González-Pinto, Covadonga M Díaz-Caneja, Iluminada Corripio, Eduard Vieta, Josefina Castro-Fornieles, Julio Bobes, Miguel Gutiérrez-Fraile, Roberto Rodriguez-Jimenez, Gisela Mezquida, Adrián Llerena, Jeronimo Saiz-Ruiz, Miguel Bernardo, PEPs GROUP
JournalSchizophrenia research (Schizophr Res) Vol. 193 Pg. 188-196 (03 2018) ISSN: 1573-2509 [Electronic] Netherlands
PMID28663026 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2017 Elsevier B.V. All rights reserved.
Topics
  • Adolescent
  • Adult
  • Child
  • Cohort Studies
  • Comorbidity
  • Disease Progression
  • Female
  • Humans
  • Male
  • Metabolic Diseases (diagnosis, epidemiology, etiology)
  • Mood Disorders (epidemiology, etiology)
  • Psychotic Disorders (complications)
  • Risk Factors
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: